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Meropenem, a second carbapenem antimicrobial agent with a broad spectrum
of activity, is used to treat sepsis and resistant-bacterial infections in veterinary
medicine. The objective of this study was to identify the pharmacokinetics of
meropenem in dogs receiving intermittent hemodialysis (IHD) and to determine
the proper dosing in renal failure patients receiving IHD. Five healthy beagle
dogs were given a single i.v. dose of 24 mg/kg of meropenem and received IHD.
The blood flow rate, dialysate flow, and ultrafiltration rate were maintained at
40 mL/min, 300 mL/min, and 40 mL/h, respectively. Blood samples were col-
lected for 24 h from the jugular vein and from the extracorporeal arterial and
venous line. Urine samples and dialysate were also collected. The concentra-
tions of meropenem were assayed using HPLC/MS/MS determination. The peak
plasma concentration was 116  37 lg/mL at 15 min. The systemic clear-
ance was 347  117 mL/h/kg, and the steady-state volume of distribution was
223  67 mL/kg. Dialysis clearance was 71.1  34.3 mL/h/kg, and the
extraction ratio by hemodialysis was 0.455  0.150. The half-life (T1/2) in
dogs with IHD decreased compared with those without IHD, and the reduction
in T1/2 was greater in renal failure patients than in normal patients. Sixty-nine
percent and 21% of the administered drug were recovered by urine and dialy-
sate in the unchanged form, respectively. In conclusion, additional dosing of
24 mg/kg of meropenem after dialysis could be necessary according to the
residual renal function of the patient based on the simulated data.
(Paper received 7 July 2015; accepted for publication 20 April 2016)
Tae-Sung Koo, Graduate School of New Drug Discovery and Development,
Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 305-764,
Korea. E-mail: kootae@cnu.ac.kr
and
Kyoung-Won Seo, College of Veterinary Medicine, Chungnam National University,
99 Daehak-ro, Yuseong-gu, Daejeon 305-764, Korea. E-mail: kwseo@cnu.ac.kr
INTRODUCTION
Antibiotics are frequently used in patients receiving renal
replacement therapy (RRT). According to reports in human
medicine, infectious disease and acute kidney injury (AKI)
often occur concurrently, and the related mortality is high
(Hoste et al., 2006; Roberts et al., 2012). In veterinary medi-
cine, infection is reported as the second most common etiology
of AKI (Eatroff et al., 2012), and the incidence of AKI sec-
ondary to sepsis is 12% (Kenney et al., 2010). In renal disease,
neutrophil dysfunction can make patients susceptible to infec-
tions (Cendoroglo et al., 1999). Therefore, antibiotic use is
mandatory in patients with renal failure.
Meropenem is a second carbapenem antimicrobial agent
with broad spectrum activity against gram-positive, gram-
negative, and anaerobic bacteria (Bidgood & Papich, 2002).
Meropenem is used to treat bacteremia, sepsis, and resistant-
bacterial infections in veterinary medicine (Papich, 2013).
Meropenem has higher activity against Pseudomonas aerugi-
nosa and Enterobacteriaceae than does imipenem in vitro
(Jones et al., 1989). It is also stable at dehydropeptidase-1
(DHP-1) and is less nephrotoxic than imipenem, and adverse
reactions are rarely observed (Chimata et al., 1993; Hellinger
& Brewer, 1999; Bidgood & Papich, 2002; Plumb, 2011).
The molecular weight of meropenem is 386.46 Da, and mer-
openem has low-protein binding (11.87%) and low volume of
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distribution (372  53 mL/kg) (Bidgood & Papich, 2002).
These pharmacokinetic properties of meropenem allow it to be
readily removed by RRT.
Despite the significance of the pharmacokinetic data for determi-
nation of the proper dosing, information about the pharmacokinet-
ics of meropenem in dogs receiving intermittent hemodialysis
(IHD) is not available. Therefore, we investigated the pharmacoki-
netics of meropenem in dogs receiving IHD and determined the
proper dosing in renal failure patients receiving IHD.
MATERIALS AND METHODS
Animals
Five adult beagle dogs (five males) weighing from 7.94 to 11.4 kg
were included in this study. The dogs were maintained for experi-
mental purposes, housed individually in cages, fed commercial dry
food, and given free access to water. All dogs were screened by
physical examination, thoracic radiography, complete blood cell
count, serum biochemistry, and urinalysis. All dogs were fasted for
12 h before drug administration and were fed after dialysis. The
experiment was conducted in accordance with the Guide for the
Care and Use of Laboratory Animals and was approved by Chung-
nam National University (no.CNU-00526).
Drug administration
Meropenem trihydrate (Meropen, Yuhan Co., Seoul, Korea)
was prepared in normal saline at 20 mg/mL. Dogs were
administered a single dose of 24 mg/kg of meropenem intra-
venously over a period of 15 min through the cephalic vein.
Dialysis design
A 14-French, 15-cm, double-lumen catheter (Hemodialysis
catheter, Arrow International) was placed in the right jugular
vein under general anesthesia. Anesthesia was induced and
maintained with isoflurane (Ifran, Hana Pharm). Catheter
placement was performed 24 h before meropenem infusion.
Hemodialysis was initiated at the end of the infusion and
was performed for 5 h with a 4008 S dialyzer unit (Fresenius
Medicare Care, Homburg, Germany). A pediatric high-flux dia-
lyzer (FX paed; Fresenius Medical Care) was used as an artifi-
cial kidney, its membrane material was helixone, and the
effective surface area was 0.2 m2. The total blood volume pro-
cessed was 12 L, and the blood flow rate (Qb) was maintained
at 40 mL/min. The dialysate flow rate (Qd) was 300 mL/min.
The ultrafiltration rate was 40 mL/h, and the target volume
was 200 mL. The anticoagulation agent was heparin, and the
target ACT was 180–200 sec.
Sampling
Blood samples (<2 mL) were collected from the jugular vein at
0, 0.083, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 h after infu-
sion. Additionally, blood samples were collected from arterial
and venous lines of the extracorporeal circuit at 0, 0.083, 0.5,
1, 2, 3, 4, and 5 h after the end of infusion. Blood samples
were collected in heparinized tubes and were centrifuged at
1000 9 g for 10 min and kept at 80 °C until analysis. Urine
samples were collected through urinary catheter in three peri-
ods: from 0 to 2, 2 to 5, and 5 to 12 h after the end of infu-
sion. Spent dialysate was collected in a 100-L plastic barrel,
and a representative sample (1.5 mL) was collected in an
Eppendorf tube. The total spent dialysate volume was calcu-
lated from the dialysate flow. All samples were immediately
stored at 80 °C and protected from light until analysis.
Analytical method
An aliquot (50 lL) of internal standard solution (cephalexin
1 lg/mL in acetonitrile) and 200 lL of acetonitrile were added
to an aliquot (50 lL) of plasma to induce the precipitation of
plasma proteins. For the diluted urine and dialysate samples,
400 lL of acetonitrile was added. Separation was achieved using
a HILIC Silica (Waters Atlantis, 3 lm, 2.1 9 50 mm) column
with an isocratic mobile phase comprising 0.2% formic acid in
40:60 (v/v) water:acetonitrile, and detection was performed
using a tandem quadrupole mass spectrometer (API 4000;
Applied Biosystems/MDS SCIEX, Foster City, CA, USA) by multi-
ple-reaction monitoring via an electrospray ionization source
at m/z 684.2 to 141.0 for meropenem and m/z 348.2 to 158.1
for cephalexin. The quantifiable range for plasma samples was
from 0.01 to 10 lg/mL with a coefficient of variation (CV) less
than 14.3% and relative error (RE) less than 11.9% except
0.01 ng/mL (18.2%). In the case of urine, the quantifiable range
was from 0.03 to 30 lg/mL with CV less than 7.46% and RE less
than 11.0%. In the case of dialysate, the quantifiable range
was from 0.01 to 1 lg/mL with CV less than 12.0% except
0.01 ng/mL (19.8%) and RE less than 11.2%. The recovery was
over 95% in all matrixes. Like Huang’s report (Huang et al.,
2014), significant matrix effect was observed in all matrices (11.4,
19.1 and 16.6% in plasma, urine, and dialysate, respectively) but
that effect did not affect the result. The retention times of merope-
nem and cephalexin were 1.89 min and 0.84 min, respectively.
Pharmacokinetic analysis
The plasma concentration–time profile for each dog was ana-
lyzed using the WinNonlin 4.1 (Pharsight) program to deter-
mine the pharmacokinetic parameters. To determine the
optimal model and weight schemes, values determined with
Akaike’s information criterion (AIC) and Schwarz Bayesian
Criterion (SBC) were compared. Goodness of fit was assessed
statistically by the F-test.
Renal clearance (CLR) and dialysis clearance (CLD) were
calculated as
CLR orD ¼ Amounturine or dialysate=AUC01 ð1Þ
CLD and the extraction ratio by hemodialysis (ERD) were cal-
culated by the following equations (Qp: pumping rate for
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plasma, calculated as Qb * (1-Hematocrit ratio). CA: Concentra-
tion of arterial line. CV: Concentration of venous line. Quf:
Ultrafiltration rate. Qb: Blood flow rate.) (Gotch, 1976).
CLD ¼ ½Qp  CA  ðQp QufÞ  CV =CA ð2Þ
ERD ¼ CLD=½Qpþ ðQp QufÞ=2 ð3Þ
Only values during IHD were used for the pharmacokinetic
analysis, and the parameters were calculated for each animal
and then averaged.
Determination of dosage regimen
Plasma concentrations were simulated to determine the mero-
penem dosage regimen, based on mean plasma concentration–
time profiles. A y2-weighted two-compartment model was used
to analyze results at a constant rate of intravenous infusion
and with first-order output. In calculating CL for anuric renal
failure and IHD, the value of CLR and CLD was subtracted and
added, respectively. The change of renal function and the
application of hemodialysis were assumed to affect the elimina-
tion rate constant (kel) alone.
For antimicrobial effect of carbapenem drugs, the amount of
time that the free drug concentration remains above MIC
(T>MIC) should be 33–40% of the drug (Drusano & Hutchison,
1995; Mouton et al., 2000). Due to the lack of minimal inhibi-
tory concentration (MIC) data for meropenem in veterinary
medicine, the MIC value for meropenem in humans was used.
Considering its resistance against infection, such as with Pseu-
domonas, and the difference in plasma protein binding (PPB)
between dog and human, the MIC of meropenem in dogs was
regarded as 1.1 lg/mL.
RESULTS
The total amount of meropenem administered to each dog was
230  40 mg. No adverse events were observed after the
administration of meropenem.
The average plasma concentration–time profiles of merope-
nem are described in Fig. 1. There was a multi-exponential
decline in the plasma meropenem level, and plasma merope-
nem was no longer detected in any dogs 12 h after the end of
infusion. Analysis showed that a three-compartment model at
a constant rate of intravenous infusion did not fit the concen-
tration data. Based on the values obtained from the sum of
weighted residual squares, as well as AIC and SBC criteria, of
one- and two-compartment model analyses, the two-compart-
ment model with a constant rate of intravenous infusion was
determined to optimally fit the plasma concentration data
(Table 1). An F-test also showed that the y2-weighted two-
compartment model was superior to other models (data not
shown).
The pharmacokinetic data using y2-weighted two-compart-
ment model with constant rate intravenous infusion and
constant rate intravenous infusion are described in Table 1.
After the i.v. infusion of meropenem, the peak plasma concen-
tration (Cmax) was 116  37 lg/mL at 15 min. The mean sys-
temic plasma clearance (CL) was 347  117 mL/h/kg, and
the mean steady-state volume of distribution (Vss) was
223  67 mL/kg.
The mean amount of meropenem in urine in the first 2 h
after the end of infusion was 142  90 mg; for 0–5 h, it was
158  71 mg; and for 0–12 h, it was 159  72 mg. The
main proportion (68.9%) of the administered drug was
excreted by the urine in an unchanged form, and 89.2% of the
urine excretion occurred in the first 2 h. The mean amount of
meropenem recovered from the dialysate was 47.2  22.8 mg,
and this value was approximately 20.5% of the administered
drug. Based on the concentration of meropenem in the dialy-
sate, dialysis clearance (CLD) was calculated as 71.1 
34.3 mL/h/kg. As calculated using the method of Gotch, CLD
was 65.4  27.5 mL/h/kg. The mean ERD value was
0.455  0.150.
Table 2 shows the clearance and elimination half-life in dogs
with various degrees or renal functions with/without IHD. Cal-
culations were based on the pharmacokinetic data from
average concentration and performed using on equations 4
(kel: elimination rate constant)
T1=2 ¼ ln 2=kel ð4Þ
Group 1 included healthy beagle dogs with normal renal
function; the clearance of meropenem was 276 mL/h/kg,
and T1/2 was 1.14 h. If IHD were applied to this group, T1/2
would decrease to 80% of T1/2 compared with the value for
group 1 during the dialysis period. Assuming an anuric state
of renal failure, additional clearance of the dialyzer would
increase the total clearance more than twofold compared
with the 26% increase observed in groups with normal renal
function. Accordingly, the dialysis clearance of meropenem
Fig. 1. Mean plasma meropenem concentrations in five beagle dogs on
IHD after intravenous administration of meropenem (24 mg/kg).
● Jugular vein. ■ Arterial line. ▲ Venous line.
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would be expected to account for 65.7% of the total clear-
ance in the anuric renal failure group. However, applying
IHD treatment to anuric renal failure patients would cause a
significant decrease in T1/2 from 8.5 h to 2.9 h during the
dialysis period
The pharmacokinetic simulations of the plasma–time con-
centration profile of meropenem in dogs with various renal
functions and with/without IHD are described in Fig. 2.
DISCUSSION
A dosing simulation was performed based on the data from
our study to assess the adequacy of adjusting the general
dosage regimens in IHD dogs and to establish dose recommen-
dations in renal patients receiving IHD.
Previous pharmacokinetic studies of meropenem have been
performed in healthy beagle dogs (Harrison et al., 1989;
Bidgood & Papich, 2002). In our study, the total body
clearance, plasma half-life, area under curve (AUC), and vol-
ume of distribution are similar to the values determined in pre-
vious studies. According to Bidgood et al., after 20 mg/kg
meropenem infusion, the total body clearance was
392  91 mL/h/kg, and the plasma half-life was
0.67  0.07 h. The AUC and volume of distribution were
53  12 lgh/mL and 337  52 mL/kg, respectively.
Drug removal through hemodialysis was first reported by
Golper et, al (Golper et al., 1985). Thereafter, numerous studies
of drug removal during HD have been performed in human
medicine. Considerations for drug dosing in patients under
renal replacement therapy are including drug characteristics,
HD prescription, and patients’ status. Drug with low-protein
binding, low volume of distribution, and low molecular weight
and size can be significantly removed through dialyzers (Bohler
et al., 1999; Heintz et al., 2009).
In humans, meropenem and its metabolite showed signifi-
cant removal through IHD, and the possibility of underdosing
was reported (Thalhammer & Horl, 2000). Several studies con-
firmed a significant decrease in the elimination half-life during
dialysis, and the reported drug removal comprised as much as
50–70% of the administered drug (Leroy et al., 1992a,b). Addi-
tional dosing of meropenem at the end of dialysis is recom-
mended in these studies to avoid underdosing (Christensson
et al., 1992; Leroy et al., 1992a,b; Chimata et al., 1993).
Meropenem removal through IHD using a helixone mem-
brane was identified in this study. Dialysis clearance was
Table 1. Pharmacokinetic parameters of meropenem in healthy beagle dogs after intravenous infusion of meropenem (24 mg/kg for 0.25 h) during
IHD
PK Parameters Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Mean  S.D. Mean Conc.
Tmax (h) 0.250 0.250 0.250 0.250 0.250 0.250  0.000 0.250
Cmax (lg/mL) 163 124 70.2 90.0 135 116  37 116
T1/2 (h) 0.734 0.843 0.714 1.08 1.18 0.911  0.211 0.813
(0.880*)
AUC0-∞ (lgh/mL) 116 81.6 49.1 59.1 87.9 78.8  26.3 79.8
CL (mL/h/kg) 215 307 509 423 285 347  117 313
Vss (mL/kg) 152 198 310 275 181 223  67 208
Tmax = Time until maximum concentration. Cmax = Maximum concentration. T1/2 = Elimination half-life. AUC = Area under the curve.
MRT = Mean residence time. CL = Clearance. Vss = Apparent volume of distribution.
*Harmonic mean.
Table 2. Prediction of the elimination half-life based on pharmacoki-






1 Normal without IHD CLR + CLothers 1.14
216 + 37 = 249 (T1/2)
2 Normal with IHD CLR + CLothers 0.81
216 + 33 + 64 = 313 (0.8T1/2)
3 Anuric renal failure CLothers 5.59
33 (7.5T1/2)
4 Anuric renal failure
with IHD
CLothers + CLD 2.90
33 + 64 = 97 (2.6T1/2)
CLR = Renal clearance. CLother = Nonrenal clearance. CLD = Dialysis
clearance. T1/2 = Elimination half-life.
Fig. 2. Simulated mean plasma–time concentration profile of merope-
nem (single dose, 24 mg/kg, i.v.) in dogs with normal renal function
+IHD (—), normal renal function (— —), 75% renal failure + IHD
(——), 75% renal failure (), 100% renal failure + IHD (- - - - -),
and 100% renal failure (—).
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calculated from the measurement of the meropenem concen-
tration in the recovered dialysate and was calculated using the
method of Gotch (Gotch, 1976). The two clearances were simi-
lar, and approximately 20.5% of the administered meropenem
was removed by the dialyzer.
In general, serious renal failure reduces plasma protein bind-
ing. However, the PPB of meropenem in dogs was reported to be
about 11% (Bidgood & Papich, 2002), suggesting that altered
protein binding had negligible impact on renal failure and
hemodialysis. Furthermore, renal dysfunction would be expected
to cause decreased drug clearance proportionally to the residual
renal function, and the dogs on IHD showed decreased T1/2 and
low plasma concentrations compared with those observed in
off-dialysis dogs with the same renal function.
According to this simulation, the dosage regimen of 24 mg/kg,
i.v., once daily is inadequate in both the on- and off-dialysis
groups with normal renal function. In dogs with normal renal
function, i.v. infusion of 24 mg/kg of meropenem every 8 h
was adequate, regardless of the IHD treatment. In off-dialysis
dogs whose renal function has failed by up to 75%, 24 mg/kg
of meropenem once daily maintains its plasma concentration
for sufficient time, but not in on-dialysis dogs. Applying the
same interval to the IHD dogs would result in an underdosing
of meropenem because T>MIC does not exceed 40% of the dos-
ing interval. Therefore, repetitive dosing of 24 mg/kg of mero-
penem after IHD may be required in these dogs. In contrast to
dogs with 75% renal failure, anuric patients with IHD do not
require meropenem re-dosing. In accordance with this simula-
tion, 24 mg/kg of meropenem every 72 h would be sufficient
to obtain a bacterial killing effect in anuric, off-dialysis dogs,
and applying the same dosage to anuric patients receiving IHD
would also be sufficient. Therefore, re-dosing in anuric dogs
receiving IHD is not necessary.
As noted above, IHD treatment does not always correlate to
re-dosing of meropenem in dogs, unlike in the human dosing
guidelines. The necessity of repetitive dosing did not show con-
sistency among groups, and this difference is thought to be
caused by the residual renal function of the patient. A previous
study reported the influence of the residual renal function of
the patient on meropenem clearance (Isla et al., 2005). It was
explained that even with the dialysis clearance of meropenem,
renal clearance was the major route of elimination of the drug,
and drug clearance could be influenced significantly by the
patient’s renal function.
However, recent studies in human patients reported that
maintaining T>MIC at 33–40% of the dosing interval did not
achieve the desired antimicrobial effects. In one study, optimal
clinical outcomes were achieved when T>MIC was maintained
at over 75% of the dosing interval (Ariano et al., 2005), sug-
gesting that the dosage regimens used in our study were insuf-
ficient. Further pharmacodynamic studies are required to
assess the antimicrobial effect of meropenem and relationship
between T>MIC and bacterial killing effect in vivo.
This study is limited to the specific settings of IHD (blood
flow, ultrafiltration rate, dialyzer membrane) and was con-
ducted in healthy subjects; therefore, meropenem removal
could be altered in different settings of IHD and in actual
patients with different renal function.In addition, dosing
requirements can vary in individual patients, as the simulated
data are based on average plasma concentrations.
Multiple-dosing studies in patients with various degrees of
renal failure at different IHD settings should be performed to
obtain a conclusive recommendation for a dosage regimen.
CONCLUSIONS
This study investigated the pharmacokinetics of meropenem in
healthy beagle dogs receiving IHD. Meropenem removal through
IHD was identified, and underdosing occurred. Repetitive dosing
of 24 mg/kg of meropenem after dialysis could be required
depending on the residual renal function of the patient.
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